Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (321-330 of 384) with videos related to

Pageof 39
Sort By:
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
Journal of the National Cancer Institute|April 15, 2016
miR-141-Mediated Regulation of Brain Metastasis From Breast CancerBisrat G Debeb, Lara Lacerda, Simone Anfossi, et al.
Cancer Research|June 10, 2016
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 NanoparticlesXi Jiang, Jason Bugno, Chao Hu, et al.
The Lancet. Oncology|December 20, 2014
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S Topp, Nicola Gökbuget, Anthony S Stein, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood Advances|December 24, 2019
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomesCaner Saygin, Ashwin Kishtagari, Ryan D Cassaday, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Haematologica|January 19, 2023
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitorsGregory W Roloff, Frank Wen, Aubrianna Ramsland, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2006
Gene expression profiles in acute myeloid leukemia with common translocations using SAGESanggyu Lee, Jianjun Chen, Guolin Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2013
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemiaPing Chen, Colles Price, Zejuan Li, et al.
Pageof 39

Showing results (321-330 of 384) with videos related to

Sort By:
Pageof 39
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
Journal of the National Cancer Institute|April 15, 2016
miR-141-Mediated Regulation of Brain Metastasis From Breast CancerBisrat G Debeb, Lara Lacerda, Simone Anfossi, et al.
Cancer Research|June 10, 2016
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 NanoparticlesXi Jiang, Jason Bugno, Chao Hu, et al.
The Lancet. Oncology|December 20, 2014
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S Topp, Nicola Gökbuget, Anthony S Stein, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood Advances|December 24, 2019
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomesCaner Saygin, Ashwin Kishtagari, Ryan D Cassaday, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Haematologica|January 19, 2023
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitorsGregory W Roloff, Frank Wen, Aubrianna Ramsland, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2006
Gene expression profiles in acute myeloid leukemia with common translocations using SAGESanggyu Lee, Jianjun Chen, Guolin Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2013
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemiaPing Chen, Colles Price, Zejuan Li, et al.
Pageof 39